| Literature DB >> 28589099 |
Adrien A Blisnick1, Thierry Foulon2, Sarah I Bonnet1.
Abstract
New tick and tick-borne pathogen control approaches that are both environmentally sustainable and which provide broad protection are urgently needed. Their development, however, will rely on a greater understanding of tick biology, tick-pathogen, and tick-host interactions. The recent advances in new generation technologies to study genomes, transcriptomes, and proteomes has resulted in a plethora of tick biomacromolecular studies. Among these, many enzyme inhibitors have been described, notably serine protease inhibitors (SPIs), whose importance in various tick biological processes is only just beginning to be fully appreciated. Among the multiple active substances secreted during tick feeding, SPIs have been shown to be directly involved in regulation of inflammation, blood clotting, wound healing, vasoconstriction and the modulation of host defense mechanisms. In light of these activities, several SPIs were examined and were experimentally confirmed to facilitate tick pathogen transmission. In addition, to prevent coagulation of the ingested blood meal within the tick alimentary canal, SPIs are also involved in blood digestion and nutrient extraction from the meal. The presence of SPIs in tick hemocytes and their involvement in tick innate immune defenses have also been demonstrated, as well as their implication in hemolymph coagulation and egg development. Considering the involvement of SPIs in multiple crucial aspects of tick-host-pathogen interactions, as well as in various aspects of the tick parasitic lifestyle, these molecules represent highly suitable and attractive targets for the development of effective tick control strategies. Here we review the current knowledge regarding this class of inhibitors in tick biology and tick-borne pathogen transmission, and their potential as targets for future tick control trials.Entities:
Keywords: immune responses; tick serine protease inhibitors; tick-borne pathogens; ticks; tick–host interactions
Mesh:
Substances:
Year: 2017 PMID: 28589099 PMCID: PMC5438962 DOI: 10.3389/fcimb.2017.00199
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
Tick serine protease inhibitors implicated in both tick biology/physiology and modulation of vertebrate host responses to tick bite, classified according to their inhibitor group (Serpin, Macroglobuline, Kunitz, Kazal), and the corresponding tick species.
| TAM | 420 | α2M | Tick immune defense | Kopacek et al., | |
| IrAM | 440 | α2M | Antimicrobial activity | Buresova et al., | |
| BmCI | 6.5 | Kunitz | Antimicrobial activity | Lima et al., | |
| DvKPI | 62 | Kunitz | Antimicrobial activity | Ceraul et al., | |
| Ixodidin | 7.1 | Trypsin Inhibitor Like (TIL) | Antimicrobial activity | Fogaça et al., | |
| BmSI 6-7 | 7.4, 7.3 | Trypsin Inhibitor Like (TIL) | Antimicrobial activity and tissue preservation | Sasaki et al., | |
| BmTI-A | 13.5 | Kunitz | Probable antimicrobial activity | Tanaka et al., | |
| HLS 2 | 44 | Serpin | Hemolymph clot formation | Imamura et al., | |
| HLSG-1 | 37.7 | Serpin | Hemolymph clot formation | Mulenga et al., | |
| RAS 3-4 | 43.2, 53.9 | Serpin | Hemolymph clot formation | Mulenga et al., | |
| HLSG-2 | 31.2 | Serpin | Probable blood digestion helper | Mulenga et al., | |
| HlMKI | 12 | Kunitz | Probable blood digestion helper | Miyoshi et al., | |
| HLS-1 | 41 | Serpin | Probable blood uptake and digestion helper | Sugino et al., | |
| HlChI | 6.7 | Kunitz | Probable blood digestion helper | Alim et al., | |
| RAMSP 1-3 | 32.3, 51.2, 49.5 | _ | Probable blood digestion helper | Mulenga et al., | |
| RAS-1 and -2 | 41.9, 42.7 | Serpin | Probable blood digestion helper | Mulenga et al., | |
| AAS19 | 43 | Serpin | Probable blood digestion helper | Kim et al., | |
| RMS-3 -6 -9 -13 -15 -16 -17 -21 -22 | 40-55 | Serpin | Probable blood digestion helper | Tirloni et al., | |
| BmTI-A | 13.5 | Kunitz | Probable blood digestion helper | Sasaki et al., | |
| BmTI-D | 1.6 | Kunitz | Probable blood digestion helper | Sasaki et al., | |
| AamS6 | 42 | Serpin | Probable blood digestion helper | Chalaire et al., | |
| Ixophilin | 54.4 | Kunitz | Probable blood digestion helper | Narasimhan et al., | |
| BmTIs | 6.2-18.4 | Kunitz | Tick egg production and development | Tanaka et al., | |
| RMS-3 | 40 | Serpin | Tick reproduction egg production | Rodriguez-Valle et al., | |
| RMS-6 | 40 | Serpin | Probable role in embryogenesis | Rodriguez-Valle et al., | |
| RMS-19 | 40.7 | Serpin | Role in tick development | Rodriguez-Valle et al., | |
| RMS-20 | 31.1 | Serpin | Role in tick development | Rodriguez-Valle et al., | |
| RMS-21 | 12.5 | Serpin | Probable role in embryogenesis | Rodriguez-Valle et al., | |
| RMS-22 | 10.7 | Serpin | Probable role in embryogenesis | Rodriguez-Valle et al., | |
| RmKK | 16.7 | kunitz | Probable protection of undesired egg proteolysis | Abreu et al., | |
| BmTI-6 | 33.8 | kunitz | Regulation of egg production and proteases in eggs and larvae | Andreotti et al., | |
| RsTIs | 8-18 | kunitz | Regulation of egg production and proteases in eggs and larvae | Sant'Anna Azzolini et al., | |
| Tick FRP | 32 | Kazal | Role in tick oviposition | Zhou et al., | |
| AAS19 | 43 | Serpin | Role in tick oviposition | Kim et al., | |
| Ixolaris | 15.7 | Kunitz | Blocks FVIIa/TF complex activity | Francischetti et al., | |
| Penthalaris | 35 | Kunitz | Block FVIIa/TF complex activity | Francischetti et al., | |
| BSAP1 | 9.3 | _ | Targets tissue factor (TF) | Ehebauer et al., | |
| BSAP2 | 9.1 | _ | Targets tissue factor (TF) | Ehebauer et al., | |
| IrCPI | 9.7 | Kunitz | Blocks FXII, FXI, and kallikrein activation | Decrem et al., | |
| BmTI-A | 13.5 | Kunitz | Blocks plasmin, elastase, and plasma kallikrein | Tanaka et al., | |
| Rhipilin-2 | 22 | Kunitz | Affects APTT test clotting time | Cao et al., | |
| Haemaphysalin | – | Kunitz | Blocks kallikrein-kinin system activation | Kato et al., | |
| DvKPI | 62 | Kunitz | Affects APTT test clotting time | Ceraul et al., | |
| TAP | 7 | Kunitz | Blocks FXa activity | Waxman et al., | |
| FXa inhibitor | 7 | Kunitz | Blocks FXa activity | Gaspar et al., | |
| 17 | _ | Blocks FXa activity | Joubert et al., | ||
| 15 | _ | Blocks FXa activity | Ibrahim et al., | ||
| 65 | Serpin | Blocks FXa activity | Limo et al., | ||
| AAS19 | 43 | Serpin | Blocks FXa and plasmin action | Kim et al., | |
| Amblyomin-X | 13.5 | Kunitz | Blocks FVIIa/TF complex activity and prothombin conversion | Batista et al., | |
| BmAP | 60 | _ | Thrombin inhibitor | Horn et al., | |
| Microphilin | 1.7 | _ | Thrombin inhibitor | Ciprandi et al., | |
| BmGTI | 26 | _ | Thrombin inhibitor | Ricci et al., | |
| RMS 15 | 48 | Thrombin inhibitor | Rodriguez-Valle et al., | ||
| Boophilin | 13.9 | Kunitz | Thrombin inhibitor | Macedo-Ribeiro et al., | |
| Ixin | – | _ | Thrombin inhibitor | Hoffmann et al., | |
| Iris | 43 | Serpin | Thrombin inhibitor | Leboulle et al., | |
| Madanin 1 | 67 | _ | Thrombin inhibitor | Iwanaga et al., | |
| Madanin 2 | 71 | _ | Thrombin inhibitor | Iwanaga et al., | |
| Chimadanin | 7.4 | _ | Thrombin inhibitor | Nakajima et al., | |
| HLS2 | 44 | Serpin | Weak thrombin inhibitor | Imamura et al., | |
| Hemalin | 20 | Kunitz | Thrombin inhibitor | Liao et al., | |
| IxSc-1E1 | 45 | Serpin | Thrombin inhibitor | Ibelli et al., | |
| Americanin | 12 | _ | Thrombin inhibitor | Zhu et al., | |
| Amblin | 17.4 | Kunitz | Thrombin inhibitor | Lai et al., | |
| Variegin | 3.7 | _ | Thrombin inhibitor | Kazimírová et al., | |
| Hyalomin 1-4 | 8.4, 8.5, 8.2, 7.4 | _ | Thrombin inhibitor | Francischetti et al., | |
| NTI 1 | 3.4 | _ | Thrombin inhibitor | Ibrahim et al., | |
| NTI 2 | 14.9 | _ | Thrombin inhibitor | Ibrahim et al., | |
| Rhipilin-1 | 18 | Kunitz | Thrombin inhibitor | Gao et al., | |
| RHS-1 | 41.9 | Serpin | Thrombin inhibitor | Yu et al., | |
| RHS-2 | 42.7 | Serpin | Thrombin inhibitor | Yu et al., | |
| Calcaratin | 14.5 | _ | Thrombin inhibitor | Motoyashiki et al., | |
| – | _ | Thrombin inhibitor | Anastopoulos et al., | ||
| Ornithodorin | 12 | Kunitz | Thrombin inhibitor | van de Locht et al., | |
| Savignin | 12 | _ | Thrombin inhibitor | Mans et al., | |
| Monobin | 15 | Kunitz | Thrombin inhibitor | Mans et al., | |
| BmSI-7 | 7.3 | _ | Elastase inhibitor | Sasaki et al., | |
| Lopsins | 43-44 | Serpin | Probable anti-inflammatory action | Mulenga et al., | |
| AamS6 | 42 | Serpin | Inhibits elastase, plasmin, and chymase | Chalaire et al., | |
| AAS19 | 43 | Serpin | Inhibits plasmin | Syrovets et al., | |
| Iris | 43 | Serpin | Inhibits elastase-like proteases and suppresses pro-inflammatory cytokine secretion | Leboulle et al., | |
| Ipis-1 | 41.7 | Serpin | Modulates CD14+ cells activation | Toyomane et al., | |
| IRS-2 | 41.9 | Serpin | Modulates T cell differentiation, T17 cell maturation and inhibits chymase and cathepsin G | Chmelar et al., | |
| Tryptogalinin | 10.3 | Kunitz | Inhibits elastase, tryptase, plasmin, matryptase | Payne and Kam, | |
| Tdpi | 11.1 | Kunitz | Inhibits plasmin and tryptase | Paesen et al., | |
| RMS-3 | 40 | Serpin | Probable interaction/modulation of B cell action | Rodriguez-Valle et al., | |
| BmTI 2 -3 | 17,1, 3.1 | Kunitz | Inflammatory response modulation | Sasaki et al., | |
| BmCI | 6.5 | Kunitz | Pro-apoptotic role and inhibits cell proliferation | Lima et al., | |
| Haemangin | 14.1 | Kunitz | Abolishes angiogenesis and neovascularization | Islam et al., | |
| BmTI-A | 13.5 | Kunitz | Inhibits plasma kallikrein, plasmin, and elastase, cell proliferation and migration | Soares et al., | |
| Amblyomin-X | 13.5 | Kunitz | Tumor cell cycle alteration, proteasome inhibitor, caspase cascade activation, angiogenesis repressor | Chudzinski-Tavassi et al., | |
| BmTI-A | 13.5 | Kunitz | Limits | Rachinsky et al., | |
| DvKPI | 62 | Kunitz | Modulates Rickettsia development | Ceraul et al., | |
| IrSPI | 12 | Kunitz | Modulates | Liu et al., | |
| Ixophilin | 54.4 | Kunitz | Probable role in | Narasimhan et al., | |
| RAS-1 | 41.9 | Serpin | Impacts engorgement and tick viability | Imamura et al., | |
| RAS-2 | 42.7 | Serpin | Impacts engorgement and tick viability | Imamura et al., | |
| BmTIs | 6.2-18.4 | Kunitz | Impacts tick viability and engorged tick weight | Andreotti et al., | |
| HLS-1 | 41 | Serpin | Impacts tick viability and the developmental cycle | Sugino et al., | |
| RmLTI | 46 | Kunitz | Impacts egg eclosion, viability, and larval hatchability | Andreotti et al., | |
Figure 1Representative schematic diagrams of secondary structures of the four types of serine protease inhibitors: serpins, α2 macroglobulins, Kunitz-type inhibitors, and Kazal-type inhibitors. Loops, β-sheets, and α-helices are labeled with blue, yellow, and red, respectively. (A) IRS 2 serpin from the I. ricinus tick showing the three β-sheets A, B, and C (Chmelar et al., 2011; PDB accession number: 3NDA). The green arrow represents the additional strand (s4A) formed after proteolysis, resulting in Reactive Center Loop cleavage, and insertion of the amino-terminal portion into the A β-sheet. (B) Human α2 macroglobulin complement component 5 in native homodimer conformation (Fredslund et al., 2008; PDB accession number: 3CU7). (C) Kunitz-type inhibitor Tick-Derived Protease Inhibitor (TDPI) from R. appendiculatus harboring one Kunitz domain composed of β-sheets and an α-helix stabilized by three highly conserved disulphide bridges (Paesen et al., 2007; PDB accession number: 2UUX). (D) Kazal-type inhibitor Dipetalin from blood-sucking insect Dipetalogaster maximus. harboring one Kazal domain composed of one α-helix with adjacent ß-sheets and loop (Schlott et al., 2002; PDB accession number: 1KMA).
Figure 2Schematic representation of a tick during feeding. Several tick serine protease inhibitors identified in different tick species and implicated in both tick biology/physiology and modulation of the vertebrate host responses to tick bite are also indicated. The red arrow represents blood absorption. The blue arrow represents saliva injection. The red star corresponds to a tick-borne pathogen. Note that only half of the digestive tract and a single salivary gland and ovary are represented here. Boophilus microplus subtilisin inhibitors (BmSI); Boophilus microplus Chymotrypsin inhibitor (BmCI); Ixodes ricinus alpha macroglobuline (IrAM); Dermacentor variabilis Kunitz protease inhibitor (DvKPI); Tick α-Macroglobulin (TAM); Boophilus microplus trypsin inhibitor (BmTIs); R. appendiculatus Serpins (RAS); H. longicornis serine proteinase genes (HLSG); Haemaphysalis longicornis midgut Kunitz-type inhibitor (HlMKI); Haemaphysalis longicornis serpin (HLS); Haemaphysalis longicornis chymotrypsin inhibition (HlChI); R. appendiculatus Midgut Serine proteinases (RAMSP); R.B. microplus Serpin (RMS); Amblyomma americanum serpin 6 (AamS6); Amblyomma americanum serpin 19 (AAS19); R.B. microplus Kunitz kallikrein inhibitor (RmKK); I. ricinus contact phase inhibitor (IrCPI); Tick Anticoagulant Protein (TAP); Boophilus microplus Anticoagulant Protein (BmAP); B. microplus gut thrombin inhibitor (BmGTI); Nymph thrombin inhibitor (NTI); Rhipicephalus haemaphysaloides serpin (RHS); I. ricinus immunosuppressive (Iris); I. ricinus serpin (IRS); Ixodes persulcatus immunosuppressive (Ipis); I. ricinus serine protease inhibitor (IrSPI); R. microplus Larval Trypsin Inhibitor (RmLTI).
Antimicrobial activities of serine protease inhibitors of ticks (tSPI).
| Ixodidin | Fogaça et al., | ||
| Ixodidin | Fogaça et al., | ||
| BmSI 6, BmSI 7 | Sasaki et al., | ||
| BmCI | Lima et al., | ||
| BmTI-A | Rachinsky et al., | ||
| IrAM | Buresova et al., | ||
| DvKPI | Ceraul et al., | ||
| IrSPI | Liu et al., | ||
| Ixophilin | Narasimhan et al., |
Figure 3Schematic overview of the three vertebrate blood coagulation cascade pathways, with indicated tick serine protease inhibitors and their targets. The intrinsic pathway is activated following a trauma and when blood comes into contact with subepithelial cells [contact phase with XII, Prekallikrein (PK), and High Molecular Weight Kininogen molecules (HMWK)], which then results in successive activation of factors XII, XI, and IX. The IXa/VIIIa complex then activates transformation of factor X into factor Xa. The extrinsic pathway is initiated following contact between Tissue Factor (TF) from vessels and circulating factor VII. After injury, they form a complex and catalyze the activation of factor X into factor Xa. Once activated by either pathway, factor Xa complexes with its cofactor Va to form the pro-thrombinase complex, which can then convert prothrombin into thrombin. Thrombin then transforms fibrinogen into fibrin to create a plug. Black arrows represent direct activation, dotted blue lines show positive thrombin feedback, red lines correspond to tSPI inhibition targets.